ASH 2023 | Durable symptom improvement in NTD thalassemia treated with luspatercept in the BEYOND trial
Kevin Kuo, MD, MSc, FRCPC, University Health Network, Toronto, Canada, discusses data collected in the BEYOND study (NCT03342404) evaluating the long-term effect of luspatercept plus best supportive care versus placebo plus best supportive care on non-transfusion dependent beta-thalassemia (NTDT)-related symptoms over 96 weeks. In an analysis of patient-reported outcomes (PRO) data, patients on luspatercept experienced durable symptom improvement over time, whereas those on the placebo exhibited a decrease in PRO scores. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Agios Pharmaceuticals, Alexion Pharmaceuticals, Bristol Myers Squibb, Forma Therapeutics, Pfizer, Novo/Nordisk, Vertex Pharmaceuticals
Research Funding: Agios Pharmaceuticals
Honoraria: Bristol Myers Squibb, Novo/Nordisk
Board of Directors/Advisory Committee: Bioverativ, Sanofi, Sangamo
